219 related articles for article (PubMed ID: 26194553)
21. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.
Randazzo BP; Bhat MG; Kesari S; Fraser NW; Brown SM
J Invest Dermatol; 1997 Jun; 108(6):933-7. PubMed ID: 9182825
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell vaccination as a treatment modality for melanoma.
Eubel J; Enk AH
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
[TBL] [Abstract][Full Text] [Related]
23. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
Tuettenberg A; Schmitt E; Knop J; Jonuleit H
J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
[TBL] [Abstract][Full Text] [Related]
25. Severe herpes virus (HSV-2) infection in two patients with myelodysplasia and undetectable NK cells and plasmacytoid dendritic cells in the blood.
Dalloul A; Oksenhendler E; Chosidow O; Ribaud P; Carcelain G; Louvet S; Massip P; Lebon P; Autran B
J Clin Virol; 2004 Aug; 30(4):329-36. PubMed ID: 15163423
[TBL] [Abstract][Full Text] [Related]
26. Development of an effective method for dendritic cell immunotherapy of mouse melanoma.
Lee TH; Cho HK; Cho YH; Lee MG
Scand J Immunol; 2009 Aug; 70(2):85-92. PubMed ID: 19630913
[TBL] [Abstract][Full Text] [Related]
27. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
28. [Vaccination therapy of melanoma].
Schuler-Thurner B; Schuler G
J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
[No Abstract] [Full Text] [Related]
29. Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1.
Sanna A; Huang YM; Arru G; Fois ML; Link H; Rosati G; Sotgiu S
Mult Scler; 2008 Nov; 14(9):1199-207. PubMed ID: 18653740
[TBL] [Abstract][Full Text] [Related]
30. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs.
Yoneyama H; Matsuno K; Toda E; Nishiwaki T; Matsuo N; Nakano A; Narumi S; Lu B; Gerard C; Ishikawa S; Matsushima K
J Exp Med; 2005 Aug; 202(3):425-35. PubMed ID: 16061729
[TBL] [Abstract][Full Text] [Related]
31. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms.
Oku M; Ishino R; Uchida S; Imataki O; Sugimoto N; Todo T; Kadowaki N
Br J Haematol; 2021 Jan; 192(2):343-353. PubMed ID: 33216988
[TBL] [Abstract][Full Text] [Related]
33. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells.
Chaperot L; Blum A; Manches O; Lui G; Angel J; Molens JP; Plumas J
J Immunol; 2006 Jan; 176(1):248-55. PubMed ID: 16365416
[TBL] [Abstract][Full Text] [Related]
34. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
Bettahi I; Zhang X; Afifi RE; BenMohamed L
Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
[TBL] [Abstract][Full Text] [Related]
35. DC therapy for metastatic melanoma.
Ingram SB; O'Rourke MG
Cytotherapy; 2004; 6(2):148-53. PubMed ID: 15203991
[No Abstract] [Full Text] [Related]
36. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cell vaccination and immune monitoring.
Aarntzen EH; Figdor CG; Adema GJ; Punt CJ; de Vries IJ
Cancer Immunol Immunother; 2008 Oct; 57(10):1559-68. PubMed ID: 18618110
[TBL] [Abstract][Full Text] [Related]
39. Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
González FE; Chernobrovkin A; Pereda C; García-Salum T; Tittarelli A; López MN; Salazar-Onfray F; Zubarev RA
J Immunol Res; 2018; 2018():3982942. PubMed ID: 29744371
[TBL] [Abstract][Full Text] [Related]
40. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.
Guillerme JB; Boisgerault N; Roulois D; Ménager J; Combredet C; Tangy F; Fonteneau JF; Gregoire M
Clin Cancer Res; 2013 Mar; 19(5):1147-58. PubMed ID: 23339127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
